Trial · NCT05013463
Hydroxychloroquine and Indapamide in SPMS
NCT05013463, Phase 2, Unknown, University of Calgary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hydroxychloroquine and Indapamide in SPMS. Trials, record NCT05013463. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05013463
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hydroxychloroquine and Indapamide in SPMS
- NCT number
- NCT05013463
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 35 participants, estimated
- Lead sponsor
- University of Calgary
- Conditions
- Multiple Sclerosis, Secondary Progressive
- Interventions
- Hydroxychloroquine Pill, Indapamide Pill
- First posted
- 2021-08-19
- Last updated
- 2022-05-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Timed 25-Foot Walk (T25FW) | Change in Timed 25-Foot Walk performance between the 6 month and 18 month visit | quantitative ambulation performance test |
| Secondary | 9-Hole Peg Test | baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up | Brief, standardized, quantitative test of upper extremity |
| Secondary | Symbol Digit Modalities Test | baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up | measures cognitive processing speed and working memory |
| Secondary | Functional Systems and Expanded Disability Status Scale (EDSS) | baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up | Standard measure of neurologic impairment that is used to describe disability in MS. The neurological assessment comprises seven functional system on a scale of 0 (no disability) to 5 or 6 (more severe disability). EDSS steps 5.0 to 9.5 are defined by the impairment to walking. |
| Secondary | Modified Fatigue Impact Scale (MFIS) | baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up | Structured, self-report questionnaire with 21 items concerning how fatigue impact patients quality of life, using a scale that ranges from 0 ("no problem") to 4 ("extreme problem"). Scores are then tallied to produce an overall score with a potential maximum of 160. |
| Secondary | Multiple Sclerosis Quality of Life Scale 54 item version | baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up | 54-item multidimensional health-related quality of life measure that combines both generic and MS-specific items |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05013463
GET https://conductscience.org/api/trials/v1/NCT05013463/registered